Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 4/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.35 |
| ▸ | MTOR | P42345 | 4/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660485 | 0.91 | GABRG2 (0.51) | GABRG2GABRB3GABRA2PIK3CAMTOR | |
| SCHEMBL4919925 | 0.88 | GABRG2 (0.53) | GABRG2GABRB3GABRA2BRD9BRD7 | |
| SCHEMBL2669400 | 0.86 | PIK3CA (0.35) | PIK3CAMTORBRD9BRD7MAOA | |
| SCHEMBL2669389 | 0.85 | PIK3CA (0.38) | GABRG2GABRB3GABRA2PIK3CAMTOR | |
| SCHEMBL2660640 | 0.84 | PIK3CA (0.42) | GABRG2GABRB3GABRA2PIK3CAMTOR | |
| SCHEMBL2660625 | 0.84 | GABRG2 (0.39) | GABRG2GABRB3GABRA2PIK3CA | |
| SCHEMBL2669390 | 0.84 | GABRG2 (0.40) | GABRG2GABRB3GABRA2PIK3CA | |
| SCHEMBL2669388 | 0.84 | GABRG2 (0.46) | GABRG2GABRB3GABRA2 | |
| SCHEMBL2659925 | 0.83 | GABRG2 (0.46) | GABRG2GABRB3GABRA2 | |
| SCHEMBL2669391 | 0.82 | GABRG2 (0.44) | GABRG2GABRB3GABRA2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.